Limits...
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).

Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Bröcker EB, Neumann C, Rünger TM, Schuler G, von den Driesch P, Müller I, Paul E, Patzelt T, Reitz M - Br. J. Cancer (2002)

Bottom Line: In those patients who received sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c.IL-2 (10 x 10(6) IU m(-2), days 3-5, week 4; 5 x 10(6) IU m(-2), days 1, 3, 5, week 5) and s.c.IFN-alpha (5 x 10(6) IU m(-2), day 1, week 4; days 1, 3, 5, week 5).

View Article: PubMed Central - PubMed

Affiliation: European Institute for Tumor Immunology and Prevention (EUTIP), Gotenstr. 152, 53175 Bonn, Germany. SekrProfAtzpodien@yahoo.de

Show MeSH

Related in: MedlinePlus

Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375173&req=5

fig4: Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.

Mentions: The progression free survival ranged from 0 to 62 (median 4 months) for all patients entered into the study. There was no significant difference in median progression free survival between patients treated with chemoimmunotherapy (0 months, range 0–62 months) or with chemotherapy (4 months, range 0–47 months) (Figure 4Figure 4


Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).

Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Bröcker EB, Neumann C, Rünger TM, Schuler G, von den Driesch P, Müller I, Paul E, Patzelt T, Reitz M - Br. J. Cancer (2002)

Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375173&req=5

fig4: Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.
Mentions: The progression free survival ranged from 0 to 62 (median 4 months) for all patients entered into the study. There was no significant difference in median progression free survival between patients treated with chemoimmunotherapy (0 months, range 0–62 months) or with chemotherapy (4 months, range 0–47 months) (Figure 4Figure 4

Bottom Line: In those patients who received sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c.IL-2 (10 x 10(6) IU m(-2), days 3-5, week 4; 5 x 10(6) IU m(-2), days 1, 3, 5, week 5) and s.c.IFN-alpha (5 x 10(6) IU m(-2), day 1, week 4; days 1, 3, 5, week 5).

View Article: PubMed Central - PubMed

Affiliation: European Institute for Tumor Immunology and Prevention (EUTIP), Gotenstr. 152, 53175 Bonn, Germany. SekrProfAtzpodien@yahoo.de

Show MeSH
Related in: MedlinePlus